ArticleBioinformatics advances2025
HIV multidrug class resistance prediction with a time sliding anchor approach.
Article in Bioinformatics advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Harnessing machine learning models to repurpose drugs targeting HIV-1 integrase, protease, and reverse transcriptase.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivation: The emergence of multidrug class resistance (MDR) in Human Immunodeficiency Virus (HIV) is a rare but significant challenge in antiretroviral therapy (ART). MDR, which may arise from prolonged drug exposure, treatment failures, or transmission of resistant strains, accelerates disease progression and poses particular challenges in resource-limited settings with restricted access to resistance testing and advanced therapies. Early prediction of future MDR development is important to inform therapeutic decisions and mitigate its occurrence. Results: In this study, we employ various machine learning classifiers to predict future resistance to all four major antiretroviral drug classes using features extracted from clinical HIV sequence data. We systematically explore several variations of the problem that differ in the pre-existing resistance level and the temporal gap between sample collection and observed MDR occurrence. Our models show the ability to predict multidrug class resistance even in the most challenging variations, albeit at a reduced accuracy. Feature importance analysis reveals that our models primarily utilize known drug resistance mutations for easier classification tasks, but rely on new mutations for the difficult task of distinguishing four class drug resistance from three class drug resistance. Availability and implementation: All analysis was performed using the Euresist Integrated DataBase (EIDB). Researchers wishing to reproduce, validate or extend these findings can request access to the latest EIDB release via the Euresist Network.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.